CN101700216B - 一种天然芳香水剂及其制备方法和应用 - Google Patents
一种天然芳香水剂及其制备方法和应用 Download PDFInfo
- Publication number
- CN101700216B CN101700216B CN2009102729655A CN200910272965A CN101700216B CN 101700216 B CN101700216 B CN 101700216B CN 2009102729655 A CN2009102729655 A CN 2009102729655A CN 200910272965 A CN200910272965 A CN 200910272965A CN 101700216 B CN101700216 B CN 101700216B
- Authority
- CN
- China
- Prior art keywords
- aromatic water
- preparation
- preparing
- component
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 40
- 125000003118 aryl group Chemical group 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 28
- 241000628997 Flos Species 0.000 claims abstract description 9
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 8
- 230000000840 anti-viral effect Effects 0.000 claims abstract description 8
- 235000013361 beverage Nutrition 0.000 claims abstract description 8
- 239000000645 desinfectant Substances 0.000 claims abstract description 7
- 230000009977 dual effect Effects 0.000 claims abstract description 4
- 235000013305 food Nutrition 0.000 claims abstract description 4
- 238000004140 cleaning Methods 0.000 claims description 14
- 239000012459 cleaning agent Substances 0.000 claims description 12
- 239000003206 sterilizing agent Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 9
- 239000000341 volatile oil Substances 0.000 claims description 8
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 7
- 239000002547 new drug Substances 0.000 claims description 7
- 238000004821 distillation Methods 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 238000001228 spectrum Methods 0.000 claims description 3
- 210000004877 mucosa Anatomy 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 229940034610 toothpaste Drugs 0.000 claims description 2
- 239000000606 toothpaste Substances 0.000 claims description 2
- 238000004128 high performance liquid chromatography Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 15
- 238000011161 development Methods 0.000 abstract description 8
- 239000003443 antiviral agent Substances 0.000 abstract description 6
- 241000196324 Embryophyta Species 0.000 abstract description 3
- 240000006927 Foeniculum vulgare Species 0.000 abstract description 2
- 235000004204 Foeniculum vulgare Nutrition 0.000 abstract description 2
- 240000002505 Pogostemon cablin Species 0.000 abstract description 2
- 235000011751 Pogostemon cablin Nutrition 0.000 abstract description 2
- 230000008901 benefit Effects 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 abstract 1
- 235000003097 Artemisia absinthium Nutrition 0.000 abstract 1
- 240000001851 Artemisia dracunculus Species 0.000 abstract 1
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 abstract 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 abstract 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 abstract 1
- 241000234653 Cyperus Species 0.000 abstract 1
- 241000546273 Lindera <angiosperm> Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 244000273928 Zingiber officinale Species 0.000 abstract 1
- 235000006886 Zingiber officinale Nutrition 0.000 abstract 1
- 239000001138 artemisia absinthium Substances 0.000 abstract 1
- 235000017803 cinnamon Nutrition 0.000 abstract 1
- 238000000605 extraction Methods 0.000 abstract 1
- 235000008397 ginger Nutrition 0.000 abstract 1
- 210000004400 mucous membrane Anatomy 0.000 abstract 1
- 230000008092 positive effect Effects 0.000 abstract 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 abstract 1
- 241000700605 Viruses Species 0.000 description 17
- 241000894006 Bacteria Species 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 10
- 241000712461 unidentified influenza virus Species 0.000 description 10
- 238000011160 research Methods 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 7
- 206010022000 influenza Diseases 0.000 description 7
- 206010069767 H1N1 influenza Diseases 0.000 description 6
- 241000191967 Staphylococcus aureus Species 0.000 description 6
- 201000010740 swine influenza Diseases 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 206010059866 Drug resistance Diseases 0.000 description 5
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 208000001848 dysentery Diseases 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000007791 liquid phase Substances 0.000 description 5
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000002155 anti-virotic effect Effects 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 244000063299 Bacillus subtilis Species 0.000 description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 description 3
- 241000712431 Influenza A virus Species 0.000 description 3
- 240000005819 Magnolia denudata Species 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229960002194 oseltamivir phosphate Drugs 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 241000193738 Bacillus anthracis Species 0.000 description 2
- 241000606124 Bacteroides fragilis Species 0.000 description 2
- 244000080208 Canella winterana Species 0.000 description 2
- 235000008499 Canella winterana Nutrition 0.000 description 2
- 241000186216 Corynebacterium Species 0.000 description 2
- 241000186427 Cutibacterium acnes Species 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000007358 Magnolia biondii Species 0.000 description 2
- 241001135223 Prevotella melaninogenica Species 0.000 description 2
- 241000223238 Trichophyton Species 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 206010013023 diphtheria Diseases 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000037797 influenza A Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- PIRWNASAJNPKHT-SHZATDIYSA-N pamp Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)N)C(C)C)C1=CC=CC=C1 PIRWNASAJNPKHT-SHZATDIYSA-N 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 229940055019 propionibacterium acne Drugs 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 231100000816 toxic dose Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 241001290610 Abildgaardia Species 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 241000186041 Actinomyces israelii Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 240000004510 Agastache rugosa Species 0.000 description 1
- 235000010686 Agastache rugosa Nutrition 0.000 description 1
- 235000008658 Artemisia capillaris Nutrition 0.000 description 1
- 241000092668 Artemisia capillaris Species 0.000 description 1
- 235000003069 Artemisia scoparia Nutrition 0.000 description 1
- 241001249148 Artemisia scoparia Species 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 241000194103 Bacillus pumilus Species 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 241000606123 Bacteroides thetaiotaomicron Species 0.000 description 1
- 241000606215 Bacteroides vulgatus Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000205571 Caulophyllum Species 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 235000021511 Cinnamomum cassia Nutrition 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000125183 Crithmum maritimum Species 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 241001480035 Epidermophyton Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010019705 Hepatic pain Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000146029 Lindera aggregata Species 0.000 description 1
- 241000007370 Magnolia sprengeri Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000191938 Micrococcus luteus Species 0.000 description 1
- 241001299895 Microsporum ferrugineum Species 0.000 description 1
- 241000736199 Paeonia Species 0.000 description 1
- 241000606210 Parabacteroides distasonis Species 0.000 description 1
- 241000191992 Peptostreptococcus Species 0.000 description 1
- 206010035737 Pneumonia viral Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000223229 Trichophyton rubrum Species 0.000 description 1
- 241001480046 Trichophyton schoenleinii Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 241001464837 Viridiplantae Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001716 anti-fugal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012372 quality testing Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 208000009421 viral pneumonia Diseases 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种天然芳香水剂及其制备方法,涉及一种药食两用饮料,抗病毒药物和清洁消毒剂。本天然芳香水剂包括第一、二组分;第一组分:肉桂10~14%,广藿香6~10%,小茴香6~10%,香附6~10%,乌药6~10%,生姜10~14%,白芍6~10%;第二组分:茵陈10~14%,桂皮10~14%,辛夷花10~14%。天然芳香水剂的应用有:①制备卫生用品;②制备消毒剂;③制备与粘膜接触的消毒剂;④制备中药抗病毒抗细菌的新药;⑤制备药食物两用植物绿色饮料。本发明具有下列优点和积极效果:①效果明显,安全可靠;②提取简单,易于实现;③成本低廉,原料来源广泛;④天然绿色,可持续发展。
Description
技术领域
本发明涉及药食两用饮料、抗病毒药物和清洁消毒剂,尤其涉及一种天然芳香水剂及其制备方法和应用。
背景技术
病原微生物引起的感染性疾病严重危害人类健康,造成巨大的社会和经济损失。其中细菌引起的感染性疾病,虽然大多能应用抗生素控制,但大量使用抗生素引起的耐药性不断上升又成为新的难题。尤其是金黄色葡萄球菌的耐药率已达90%以上,同时造成的肠道菌群紊乱,更加重原发性感染。从天然药物中寻找并开发具有抗菌活性的新药,对减少细菌耐药性的产生有着积极的现实意义,因而日益受到关注。艾滋病、病毒性乙型肝炎、流感、病毒性肺炎等病毒性疾病的流行,对人类健康造成莫大的威胁,其危害已不仅仅是个人和家庭,病毒本身也不仅仅是医学问题,而成为全世界关注的社会和经济问题。病毒感染性疾病最有效的预防手段是疫苗,但很多病毒性疾病目前都没有相应的疫苗,因而抗病毒药物的研制倍受重视,研究特异性抗病毒药物具有重要的社会意义。病毒性疾病的治疗药物发展较迟缓,主要由于病毒具有严格寄生性,与细胞关系密切,使得药物杀伤病毒的同时对机体细胞也有损害。目前国内外研究的抗病毒药物已接近50种,但真正应用于临床的只有阿昔洛韦、拉米夫定等少数几类核苷类药物,这些药物的作用靶点为病毒DNA聚合酶。它们以酶反应底物类似物的形式与正常底物竞争,直接降低或阻断病毒DNA聚合酶的活性,其共同缺点是易产生耐药毒株,抗病毒谱窄,毒副作用大,而且价格高昂。由于病毒基因在人群自然免疫和药物滥用等压力下不断发生变异,加上社会人口老年化和城市化加快等原因,某些病毒性传染不但没有得到有效控制,反而更加猖撅。研究高效低毒的抗病毒药物成为当今国际热点。同时在疾病的预防方面植物绿色消毒剂的开发和健康饮料研究方兴未艾。
目前甲型H1N1流感病毒感染正在全世界流行,秋冬为高发季节,危害人类的健康。流感病毒病毒型别种类繁多,有甲、乙、丙三型,每型又分为不同的亚型,常见病毒亚型为H1N1、H1N2、H3N1与H3N2,均可在人类或动物间传播,并极易突变产生新的亚型。H1N1的亚型在人类间或雀鸟和猪之间传播,人间传播包括1918年的流感大爆发,有大约10亿人受到感染,死亡人数高达3000万。目前流行的甲型流感病毒病原为H1N1亚型,属于A型H1N1病毒,是甲型流感病毒的一种,也是人类最常感染的流感病毒之一。目前,达菲已出现耐药性,2007~2009的流感季节,已发现具有传染性、耐达菲的流感病例,其耐药率达到12~80%(2008-2009欧美的新型流感几乎完全耐达菲),远远高于传统上季节性流感病毒的低耐药性(一般在0~2%)。因此,寻找安全有效的抗流感病毒新药,特别是自主开发具有我国自己知识产权的天然抗病毒中草药是当今抗流感病毒药物研究的发展趋势和新的途径。如何提高新药开发研究水平,使我国的中药走向国际化、市场化与标准化,建立新药研究技术平台是关键举措。目前,国内已有一些研究基地与技术平台,但产业化目标大多数是以心血管类药物、抗肿瘤药物、化学药物及生化药物为基础,完善的抗病毒绿色中药研究技术平台国内尚未建立。抗病毒药物的开发生产很大一部分为国外公司垄断。
在抗病毒中药制剂中,目前临床应用多是粗提物和煎剂的临床疗效观察,大多没有涉及到药物的有效成分和有效活性部位,疗效评价亦缺乏特异性指标,不能作为新药来评价其对特异性病毒感染的治疗效果。而且多数的中药制剂存在耗材大,资源浪费严重,成为环境污染的靶心。临床应用的抗病毒中药单方及复方制剂的严重不良反应及毒副作用也越来越限制了中药的市场认同。
发明内容
本发明的目的就在于克服现有消毒剂和抗病毒抗细菌药剂存在的缺点和不足,提供一种天然芳香水剂及其制备方法和应用。
本发明的目的是这样实现的:
一、天然芳香水剂的组分(重量百分比)
第一组分:肉桂(粗粉)10~14%,广藿香6~10%,小茴香6~10%,香附6~10%,乌药6~10%,生姜10~14%,白芍6~10%;
第二组分:茵陈10~14%,桂皮10~14%,辛夷花10~14%。
上述组分验证:
*所有组分下限之和小于100%,所有组分上限之和大于100%;
*每一组分的下限加其它组分的上限之和大于100%;
*每一组分的上限加其它组分的下限之和小于100%。
天然芳香水剂的药理:
肉桂为樟科植物肉桂Cinnamomum cassia Presl.的干燥树皮。味辛,性甘。抗菌、普通类杆菌、伊氏放射菌、多形类杆菌、脆弱类杆菌、卵圆类杆菌、产黑素类杆菌、痤疮丙酸杆菌、消化链球菌、吉氏类杆菌有非常明显抑菌作用。肉桂石油醚提物0.1ml对产黑素类杆菌、消化球菌、伊氏放线菌、痤疮丙酸杆菌、吉氏杆菌、多形杆菌、脆弱类杆菌、产气荚膜梭菌等有强抑制作用。桂皮煎剂在体外对真菌有抑制作用。桂皮的乙醇或乙醚浸出液浓度1%~10%对许兰氏毛癣菌等多种致病性皮肤真菌有抑制作用。桂皮油杀菌力强。对革兰氏阳性菌的抑菌力大于阴性菌。
广藿香为唇形科植物广藿香Pogostemon cablin(Blanco)Benth或藿香Agastache rugosa(Fisch et Mey)0.Ktze的全草。味辛、性微温。抗真菌作用,离体实验证明,浓度为5%~15%的藿香煎剂对许兰氏毛癣菌等多种致病性真菌有抑制作用,对藤黄八叠球菌、金黄色葡萄球菌、大肠杆菌、沙门氏菌、枯草杆菌、短小芽孢杆菌、痢疾杆菌及绿脓杆菌均有杀菌作用。
小茴香为伞形科植物茴香Foeniculum vulgare Mill.的干燥成熟果实。味辛,性温。抗菌、抗癌,茴香油对真菌、孢子、鸟型结型菌、金黄色葡萄球菌等有抗菌作用。
香附为莎草科植物莎草的干燥根茎。味辛、微苦、微甘,性平。解热镇痛,抗炎,给大鼠腹腔注射醇提物100mg/kg,对角叉莱胶和甲醛引起的足肿胀有明显的抑制作用,其作用比5~10mg/kg氢化可的松强。
乌药为樟科植物乌药Lindera aggregata(Sims)Kosterm.的干燥块根。味辛,性温。有顺气止痛,温胃散寒功能。体外试验鲜乌药叶煎剂对金黄色葡萄球菌、炭疽杆菌、乙型溶血性链球菌、白喉杆菌、大肠杆菌、绿脓杆菌、痢疾杆菌等有抑制作用。
白芍为毛莨科植物芍药paeonia lactifloraPall(栽培种)的干燥根。性味苦、酸,微寒。有平肝止痛、养血调经、敛阴止汗的功能。抗菌白芍煎剂对志贺氏痢疾杆菌,史氏痢疾杆菌、霍乱弧菌,绿脓杆菌、变形杆菌有抑制作用。水浸剂对许兰氏毛菌,共心性毛菌、铁锈色小孢子菌、奥杜盎氏小孢子菌、红色表皮癣菌、腹腔沟表皮癣菌有抑制作用。
茵陈为菊科植物滨蒿Artemisia scoparia waldst.et kit.或茵陈蒿Artemisia capillaris Thunb.的干燥地上部分。味苦、辛、微寒。功能清湿热,退黄疸。体外试验证明,茵陈煎剂对金黄色葡萄球菌、白喉杆菌、炭疽杆菌、伤寒杆菌、甲型副伤寒杆菌、绿脓杆菌、大肠杆菌、弗氏痢疾杆菌、志贺氏痢疾杆菌、脑膜炎双球菌与枯草杆菌等均有不同程度的抑制作用。
辛夷花为木兰科植物望春花Magnolia biondii Pamp.[M.fargesii(Fin.etGag)Cheng]、玉兰M.denudata Desr.[M.heptapeta(Buch.)Dandy;M.conspicuaSalisb;M.yulan Desr]或武当玉兰M.sprengeri Pamp.的干燥花蕾。味辛,性温。有散风寒功效。
二、天然芳香水剂的制备方法
天然芳香水剂的制备方法包括下列步骤:
①取第一组分净化处理,加水20倍量,按蒸馏法提取挥发油和芳香水,连续提取10倍量,收集分离挥发油后的芳香水为药食两用饮料;
②取第二组分净化处理,加水25倍量,按蒸馏法提取挥发油和芳香水,连续提取15倍量,收集挥发油和芳香水备用;
③将上述两种芳香水混合均匀即得清洁消毒剂;
④将①的芳香水和③的清洁消毒剂分别经高效液相色普检测出光谱合格后备用。
三、天然芳香水剂的应用
①制备卫生用品
a、制备洗手液,b、制备肌肤清洁液,c、制备湿巾,d、制备牙膏;
②制备消毒剂
③制备与粘膜接触的消毒剂
a、制备鼻口腔粘膜喷雾剂;b、制备蒸气吸入剂;c、制备空气消毒剂;d、制备漱口液;
④制备中药抗病毒抗细菌的新药;
⑤制备药食物两用植物绿色饮料。
本发明具有下列优点和积极效果:
①效果明显,安全可靠;
②提取简单,易于实现;
③成本低廉,原料来源广泛;
④天然绿色,可持续发展。
附图说明
图1是天然芳香水剂的高效液相色普光谱图;
其横坐标是出峰时间,纵坐标是峰值高度。
具体实施方式
下面结合实施例详细说明:
一、天然芳香水剂的最佳组分(重量百分比)
第一组分:肉桂(粗粉)12%,广藿香8%,小茴香8%,香附8%,乌药8%,生姜12%,白芍8%;
第二组分:茵陈12%,桂皮12%,辛夷花12%。
具体有:
第一处方:肉桂(粗粉)500g,广藿香333g,小茴香333g,香附333g,乌药333g,生姜500g,白芍333g;
第二处方:茵陈500g,桂皮500g,辛夷花500g。
二、实验
1、委托武汉大学病毒所进行抗甲型H1N1流感病毒的体外实验
目的:观察本天然芳香水剂体外抗甲型流感病毒H1N1(A/H1N1,A/Yamagata/120/86(H1N1))的作用,并明确其作用方式。
方法:体外观察药物抗病毒的作用方式。以利巴韦林为阳性对照药,在微量细胞培养板上,通过观察细胞病变效应(CPE)、MTT比色法检测细胞存活率和病毒抑制率、病毒滴定等方法从药物预防病毒感染、药物直接灭活病毒和药物对病毒穿入细胞后的抑制作用三个方面检测爱特欣抗A/H1N1流感病毒的活性和作用方式。
结果:芳香水和清洁消毒剂具有明显的体外抗A/H1N1流感病毒的活性,对A/H1N1流感病毒穿入细胞后具有明显的抑制病毒的生物合成的作用。清洁消毒剂对MDCK细胞的半数毒性浓度TC50为1∶2,对A/H1N1流感病毒的半数有效浓度IC50为1∶34,治疗指数TI=TC50/IC50=17.21;芳香水对MDCK细胞的半数毒性浓度TC50为1∶4,对A/H1N1流感病毒的IC50为1∶43.5,治疗指数为10.9。随着药物浓度的增加,病毒所致的CPE效应逐渐减弱,培养液中的病毒滴度也逐渐降低,而病毒抑制率则明显升高。
结论:本天然芳香水剂具有较强的体外抗流感病毒的作用,其抗病毒方式主要是通过抑制病毒的生物合成。
2、委托天津科技大学进行关于清洁消毒剂的体外抑菌试验
目的:观察清洁消毒剂的体外抑菌试验效果。
方法:采用试管法和滤纸法对系列药液进行了体外抑菌试验研究。
结果:清洁消毒剂剂对金黄色葡萄球菌、绿脓杆菌、大肠杆菌、枯草杆菌、甲型溶血性链球菌、白色念珠菌均有抑杀作用。
结论:清洁消毒剂所具的抑菌作用,为其相关消毒品的生产开发及相关药品的临床开发应用提供了实验依据。
3、质量检测结果
如图1,本天然芳香水剂经检测具有特殊的高效液相色普光谱图。
其中上图是芳香水的高效液相色普光谱图;
其中下图是清洁消毒剂高效液相色普光谱图。
Claims (3)
1.一种天然芳香水剂的制备方法,其特征在于:
第一组分:肉桂10~14%,广藿香6~10%,小茴香6~10%,香附6~10%,乌药6~10%,生姜10~14%,白芍6~10%;
第二组分:茵陈10~14%,桂皮10~14%,辛夷花10~14%;
①取第一组分净化处理,加水20倍量,按蒸馏法提取挥发油和芳香水,连续提取10倍量,收集分离挥发油后的芳香水为药食两用饮料;
②取第二组分净化处理,加水25倍量,按蒸馏法提取挥发油和芳香水,连续提取15倍量,收集挥发油和芳香水备用;
③将上述两种芳香水混合均匀即得清洁消毒剂;
④将①的芳香水和③的清洁消毒剂分别经高效液相色谱检测出光谱合格后备用。
2.按权利要求1所述的一种天然芳香水剂的制备方法,其特征在于:
第一组分:肉桂12%,广藿香8%,小茴香8%,香附8%,乌药8%,生姜12%,白芍8%;
第二组分:茵陈12%,桂皮12%,辛夷花12%。
3.按权利要求1所述的制备方法所得到的天然芳香水剂的应用,其特征在于:
①制备卫生用品
a、制备洗手液,b、制备肌肤清洁液,c、制备湿巾,d、制备牙膏;
②制备与粘膜接触的消毒剂
a、制备鼻口腔粘膜喷雾剂;b、制备蒸气吸入剂;c、制备空气消毒剂;d、制备漱口液;
③制备中药抗病毒抗细菌的新药;
④制备药食物两用植物绿色饮料。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009102729655A CN101700216B (zh) | 2009-11-27 | 2009-11-27 | 一种天然芳香水剂及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009102729655A CN101700216B (zh) | 2009-11-27 | 2009-11-27 | 一种天然芳香水剂及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101700216A CN101700216A (zh) | 2010-05-05 |
CN101700216B true CN101700216B (zh) | 2012-04-25 |
Family
ID=42155159
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009102729655A Active CN101700216B (zh) | 2009-11-27 | 2009-11-27 | 一种天然芳香水剂及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101700216B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103445264A (zh) * | 2013-09-18 | 2013-12-18 | 韦以宗 | 茵陈露饮料 |
CN103548907B (zh) * | 2013-11-11 | 2015-07-22 | 深圳市中纺滤材无纺布有限公司 | 一种本草中药抗菌组合物及中药抗菌滤网 |
CN107242990A (zh) * | 2017-06-18 | 2017-10-13 | 何家平 | 一种防治儿童蛀牙的牙膏及制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1927377A (zh) * | 2006-08-30 | 2007-03-14 | 吴正红 | 止泻擦霜及其制备方法 |
-
2009
- 2009-11-27 CN CN2009102729655A patent/CN101700216B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1927377A (zh) * | 2006-08-30 | 2007-03-14 | 吴正红 | 止泻擦霜及其制备方法 |
Non-Patent Citations (2)
Title |
---|
党小利.中草药抗真菌的研究进展.《现代医药卫生》.2008,第24卷(第10期),1513-1514. * |
武学文,高孟兰,武凌怡.芳香和温散的解毒药.《光明中医》.2008,第23卷(第2期),第224-225页. * |
Also Published As
Publication number | Publication date |
---|---|
CN101700216A (zh) | 2010-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2016176791A1 (zh) | 沉香挥发油原液在制备护肤品中的用途 | |
CN102389515B (zh) | 一种防治痤疮皮肤病的外用中药擦剂及其制备方法 | |
CN104983944A (zh) | 一种复合中药抗菌抗病毒剂及其制备方法和用途 | |
Zheng et al. | Research advances in lotus leaf as Chinese dietary herbal medicine | |
CN101700216B (zh) | 一种天然芳香水剂及其制备方法和应用 | |
Zhao et al. | Promising natural products against SARS‐CoV‐2: Structure, function, and clinical trials | |
KR101877478B1 (ko) | 여드름 개선용 화장료 조성물 | |
CN109432218A (zh) | 一种含艾叶的消炎止痒驱蚊中药膏及其制备方法 | |
CN101099787A (zh) | 一种具有显著广谱抗病毒作用的中药组合物 | |
CN102659958A (zh) | 一种蒲公英多糖提取物及其制备方法和用途 | |
CN101926861A (zh) | 用于增强非特异性免疫功能的中药兽用药的制备方法 | |
CN102973819A (zh) | 一种治疗过敏性紫癜的中药方 | |
CN101912452A (zh) | 用于增强非特异性免疫功能的兽用中药组合物及其应用 | |
KR101086811B1 (ko) | 항 인플루엔자 바이러스 효과를 갖는 천연 추출물 및 그조성물 | |
CN104288521A (zh) | 一种治疗腹泻的中药组合物及其制备方法和应用 | |
KR20150140104A (ko) | 피부개선용 화장품 제조방법 및 이를 이용한 화장품 | |
CN107333945A (zh) | 一种青蒿凉茶及其制备方法 | |
CN103446555A (zh) | 一种治疗胆囊炎的组合物中药 | |
CN103040939B (zh) | 一种治疗感冒的中药组合物及其制备方法和用途 | |
CN104784621A (zh) | 一种治疗腹泻的中药组合物及其制备方法和应用 | |
CN101612197B (zh) | 一种具有抗肠道病毒活性和/或抗甲型流感病毒活性的黄芩组合物 | |
CN113101331B (zh) | 一种百里香药茶及其制备方法和应用 | |
CN106074824A (zh) | 增强免疫力和预防治疗流感的组合物、制备工艺及用途 | |
CN101711842B (zh) | 一种纯中药消炎止痒液及其制法 | |
CN105663673A (zh) | 玉竹高异黄酮的制备方法及其在医药中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231201 Address after: 430000, Room 1.2, 4th Floor, Building 12, Tianyuan Avenue North and Guihua Road East, Jinghe Street, Dongxihu District, Wuhan City, Hubei Province Patentee after: WUHAN CAOBENXIN TECHNOLOGY Co.,Ltd. Address before: Guo CI Kou Rose Street 430051 in Hubei province Wuhan city Hanyang District No. 87 Bridge Branch Hospital of traditional Chinese Medicine Patentee before: Wu Zhenghong |
|
TR01 | Transfer of patent right |